Capitoli Giulia, Alviano Antonio Maria, Monza Nicole, Pagani Lisa, Piga Isabella, Bernasconi Davide Paolo, Greco Angela, Leni Davide, Maggioni Alice, Gatti Andrea-Valer, Maffini Fausto, Fusco Nicola, Garancini Mattia, Magni Fulvio, Galimberti Stefania, Pagni Fabio, L'Imperio Vincenzo, Denti Vanna
Bicocca Bioinformatics Biostatistics and Bioimaging Research Centre - B4, Department of Medicine and Surgery, University of Milano-Bicocca, Monza, Italy.
Biostatistics and Clinical Epidemiology, Fondazione IRCCS San Gerardo dei Tintori, Monza, Italy.
Endocrine. 2025 Aug 11. doi: 10.1007/s12020-025-04383-9.
The identification of novel molecular biomarkers may assist in the characterization of indeterminate thyroid nodules, which pose significant diagnostic challenges. Here, we aimed to explore the potential of proteomic analyses to support biomarker discovery in challenging thyroid lesions.
Linear Discriminant Analysis (LDA) was applied to Matrix-Assisted Laser Desorption Ionization Mass Spectrometry Imaging (MALDI-MSI) data from 44 thyroid neoplasms to select the most impactful molecular features for the classification of different tumor histologies, as well as for the distinction between NRAS-mutant (mNRAS) and NRAS-wild-type (wtNRAS) tumors. Relevant peaks were subsequently identified through nanoscale liquid chromatography electrospray ionization tandem mass spectrometry (nLC-ESI-MS/MS).
The LDA selected nine relevant molecular markers distinguishing noninvasive follicular thyroid neoplasms with papillary-like nuclear features (NIFTPs) from other tumor histologies (balanced accuracy = 73%), as well as 19 relevant markers able to identify mNRAS cases (balanced accuracy = 84%). Nine differentially expressed proteins were putatively identified: among them, ATP-dependent RNA helicase DDX42 showed a similar distribution between NIFTPs and papillary thyroid carcinomas (PTCs) / follicular variant PTCs (FVPTCs), while the distribution of the Histone H4 signal was similar between NIFTPs and follicular adenomas (FAs). In addition, Protein disulfide-isomerase A1 and Complement C4-B were overexpressed in wtNRAS compared to mNRAS cases, regardless of histology.
The LDA-selected features enable to distinguish NIFTPs from morphologically similar lesions and to discriminate between mNRAS and wtNRAS cases. The identified markers might complement genetic analyses and provide insights into the distinct pathogenic drivers behind the development of mNRAS compared to wtNRAS lesions.
鉴定新的分子生物标志物可能有助于明确诊断存在重大挑战的甲状腺结节。在此,我们旨在探索蛋白质组学分析在具有挑战性的甲状腺病变中支持生物标志物发现的潜力。
将线性判别分析(LDA)应用于44例甲状腺肿瘤的基质辅助激光解吸电离质谱成像(MALDI-MSI)数据,以选择对不同肿瘤组织学分类以及NRAS突变型(mNRAS)和NRAS野生型(wtNRAS)肿瘤区分最具影响力的分子特征。随后通过纳米级液相色谱电喷雾电离串联质谱(nLC-ESI-MS/MS)鉴定相关峰。
LDA选择了9个相关分子标志物,可将具有乳头状核特征的非侵袭性滤泡性甲状腺肿瘤(NIFTP)与其他肿瘤组织学区分开来(平衡准确率=73%),以及19个能够识别mNRAS病例的相关标志物(平衡准确率=84%)。推测鉴定出9种差异表达蛋白:其中,ATP依赖性RNA解旋酶DDX42在NIFTP与甲状腺乳头状癌(PTC)/滤泡状变异型PTC(FVPTC)之间显示出相似的分布,而组蛋白H4信号在NIFTP与滤泡性腺瘤(FA)之间的分布相似。此外,无论组织学如何,与mNRAS病例相比,蛋白质二硫键异构酶A1和补体C4-B在wtNRAS中均过表达。
LDA选择的特征能够将NIFTP与形态学相似的病变区分开来,并区分mNRAS和wtNRAS病例。所鉴定的标志物可能补充基因分析,并为mNRAS与wtNRAS病变发展背后不同的致病驱动因素提供见解。